Survival Benefit Linked With Adjuvant RT+ADT in Lymph Node + PCa
Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.
Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.
Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.
NEPC is an aggressive subtype of castration-resistant prostate cancer independent of androgen expression.
Metastasis-free survival correlates with overall survival in localized prostate cancer clinical trials.
Survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both.
Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.
Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.
For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.